Ketamine treatment for buprenorphine-precipitated opioid withdrawal
A case report
Bibliographic Data
| ID | 15525905 |
|---|---|
| Authors | Ezioma Gbujie (Harvard University, corresponding author), Lisa Vercollone (0009-0008-9226-9379, Brigham and Women's Hospital), Joji Suzuki (0000-0001-5659-6147, Harvard University) |
| Year | 2025 |
| Volume | 16 |
| Pages | 1586945-1586945 |
| Publication date | 2025-06-20 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2025.1586945 |
| PMID | 40621554 |
| OpenAlex | W4411501073 |
| Language | EN |
| References cited | 15 |
Ketamine may be an effective adjunctive agent in managing opioid withdrawal. Usually restricted to the intensive care unit and emergency department, this case report highlights both the potential and risks of IV ketamine on the general hospital floors. Further research is needed to better understand the safety of using ketamine to manage opioid withdrawal
Anesthesia · Buprenorphine · Ketamine · Narcotic antagonists · Opioid · Opioid use disorder · Psychiatry · Alcoholism and Thiamine Deficiency · Medicine · Opioid Use Disorder Treatment · Treatment of Major Depression · Internal Medicine
| Highly cited | No |
|---|